NRx Pharmaceuticals (NASDAQ:NRXP) Releases Earnings Results, Misses Estimates By $0.07 EPS

by · The Markets Daily

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.07), Zacks reports. The business had revenue of $0.24 million for the quarter, compared to the consensus estimate of $6.83 million.

NRx Pharmaceuticals Stock Performance

Shares of NRXP stock traded down $0.10 during trading hours on Friday, hitting $2.49. 432,261 shares of the company were exchanged, compared to its average volume of 475,505. The business’s 50-day simple moving average is $3.02 and its two-hundred day simple moving average is $2.87. NRx Pharmaceuticals has a one year low of $1.13 and a one year high of $6.01. The stock has a market capitalization of $49.33 million, a price-to-earnings ratio of -1.11 and a beta of 1.76.

Analyst Ratings Changes

A number of equities analysts have commented on NRXP shares. D. Boral Capital restated a “buy” rating and set a $34.00 price objective on shares of NRx Pharmaceuticals in a research report on Monday, November 10th. Weiss Ratings restated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of NRx Pharmaceuticals in a research report on Thursday, October 16th. Ascendiant Capital Markets upped their price objective on shares of NRx Pharmaceuticals from $46.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Finally, Zacks Research upgraded NRx Pharmaceuticals to a “hold” rating in a report on Wednesday, September 10th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $34.75.

View Our Latest Stock Report on NRXP

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in NRx Pharmaceuticals by 18.3% during the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock worth $1,765,000 after buying an additional 82,781 shares during the last quarter. Geode Capital Management LLC boosted its stake in NRx Pharmaceuticals by 27.9% during the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after buying an additional 37,598 shares in the last quarter. Finally, Two Sigma Investments LP grew its stake in shares of NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after purchasing an additional 20,880 shares during the last quarter. 4.27% of the stock is owned by institutional investors and hedge funds.

NRx Pharmaceuticals Company Profile

(Get Free Report)

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.

See Also